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• Platelet a-granules are
necessary for rapid
platelet accumulation.
vonWillebrand factor (VWF) is essential for the inductionofarterial thrombosis. In this study,
we investigated the critical role of platelet VWF in occlusive thrombosis formation at high
shear inmice that do not express platelet VWF (Nbeal22/2). Using in silico modeling, in vitro
high-shear microfluidics, and an in vivo Folts model of arterial thrombosis we reproduced
the platelet dynamics that occur under pathological flow in a stenosed vessel. Computational
fluid dynamics (CFDs) simulated local hemodynamics in a stenosis based on arterial
geometries. The model predicted shear rates, time course of platelet adhesion, and time to
occlusion. These predictions were validated in vitro and in vivo. Occlusive thrombosis
developed in wild-type control mice that had normal levels of plasma VWF and platelet VWF
in vitro and in vivo. Occlusive thrombosis did not form in the Nbeal22/2 mice that had
normal plasma VWF and an absence of platelet VWF. Occlusive thrombosis was corrected in
Nbeal22/2 microfluidic assays by the addition of exogenous normal platelets with VWF.
Combining model and experimental data, we demonstrated the necessary requirement of
platelet VWF in a-granules in forming an occlusive thrombus under high shear. These
results could inspire new pharmacological targets specific to pathological conditions and
prevent arterial thrombosis.
Introduction
Arterial thrombosis is one of the most frequent causes of morbidity and mortality in Western society.1
The rapid capture and accumulation of circulating platelets at atherosclerotic rupture sites can cause
thrombotic arterial occlusion preceding acute myocardial infarction or stroke.2,3 Under normal physiological
conditions, typical shear rates of 15 to 1600 s21 occur in the arterial vasculature.4 However, atheroscle
rotic stenosis can increase local shear rates dramatically to 5000 to 400 000 s21,5 generating high
hemodynamic forces and a prothrombogenic environment. Currently, there are no clinical therapeutics
that can unambiguously target platelets at these pathological forces at the site of occlusive thrombus
formation. Occlusive thrombus formation under these high-shear conditions can be described as
a 3-phase process of (1) initial platelet attachment to a thrombogenic surface (lag phase); (2) accelerated
growth (rapid platelet accumulation [RPA] phase); and (3) thrombus stabilization or cessation of blood flow
(occlusion phase).6
Platelet granules and their contents have a central role in controlling the balance between hemostasis
and thrombosis,7-9 by driving the 3 phases of thrombotic occlusion. Individuals who lack or have
abnormally low platelet a-granules (gray platelet syndrome [GPS]); dense granules (Hermansky-Pudlak
syndrome [HPS]); or both (ad-storage pool disease) display variable pathologies and bleeding
diathesis.8,10,11 Mouse strains that lack a-granules (Nbeal22/2)12,13 or dense granules (ruby eye)14,15 or
have defective a- and dense-granule exocytosis (VAMP2/2),15 have also been identified and echo
similar pathologies and varying bleeding tendencies, as seen in humans. Although studies involving
these mouse strains and their granule cargo vary among the different thrombosis models, it has been
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proposed that dense granules, which store and secrete ADP, ATP,
serotonin, and calcium, promote primary aggregation by activating
and recruiting platelets to injury sites.7,8 A deficiency of dense
granules or secretion of their contents typically results in a di-
minished secondary aggregation response of surrounding platelets
and delayed or attenuated initial thrombus formation in vivo.16
Dense granules initiate and support platelet aggregation, and
a-granules store and secrete adhesive proteins, such as von
Willebrand factor (VWF) and fibrinogen, that mediate thrombus
growth and stability via platelet-platelet interactions.17 Like dense
granule defects, an absence of a-granules (Nbeal2) also produces
various pathologies and bleeding.12,16,18-23 In tail-bleeding assays,
Nbeal22/2 mice exhibit increased blood loss, suggesting a de-
ficiency in hemostasis. However, in stroke models, an absence of
Nbeal2 causes no intracranial hemorrhage.13,19 In ferric chloride
and laser injury models, Nbeal22/2 mice have impaired thrombus
growth and stability, although the rate of platelet activation is
normal.12,13,24 The observations in Nbeal22/2 mice are a-granule
specific, as that dense granules and VWF in the plasma and
endothelium are normal.
Previous studies using Nbeal22/2 mice demonstrate impaired
thrombus formation under physiological conditions.12,13,24 Al-
though these critical studies have demonstrated a role for
a-granules in hemostasis and thrombosis, occlusive thrombus
formation under pathological high-shear conditions remain un-
known. a-Granules contain VWF and coagulation factors, including
fibrinogen, PF4, thrombospondin, and factor V. VWF is the dominant
protein that mediates platelet aggregation and thrombosis under high
shear.25 Coagulation factors play a lesser role under high shear,
because they are likely to be transported away from the stenosis
before the coagulation cascade is completed. Although fibrinogen
plays a more active role at low shear (,1000 s21), there are studies
showing that fibronectin can promote platelet aggregation and
thrombus growth.26 However, fibronectin concentration in a-granules
(0.19 mg/mL) is smaller than plasma concentration (0.30 mg/mL),27
which in turn have less effect on thrombosis in the absence of
a-granules.
VWF is synthesized and stored in a-granules of platelets and in the
Weibel-Palade bodies of endothelial cells. High-molecular-weight
multimers and ultralarge multimers (ULMs) of VWF are constitu-
tively secreted into the blood plasma,28,29 and are cut to smaller
multimer forms of VWF by the metalloprotease ADAMTS13
(a disintegrin and metalloproteinase with a thrombospondin type-
1 motif, member 13). The concentration of VWF in normal human
plasma is ;10 mg/mL, whereas VWF in platelet a granules are
present at the much higher concentration of 500 mg/mL.27 Under
physiological conditions, VWF does not interact with the endothe-
lium or other platelets; however, when exposed to high shear rates,
tethered VWF elongates and exposes its A1 and A2 binding
domains.30,31 The exposure of the A1 domain enables rapid A1-
platelet interactions that support rapid platelet-platelet and platelet-
endothelial interactions32 at high-shear rates,33 independent of
activation.31 In response to high shear stress, high-molecular-
weight and ultra-large VWF multimers have increased platelet
binding capacity and are more thrombogenic.34-36
Although the involvement of VWF in thrombus formation is well
established,37-43 the source of VWF at different stages of formation
is less clear. Plasma and endothelial VWF concentrations are
sufficient for initial platelet adhesion during the lag phase.39,41,44
Theoretical calculations of bond strength and growth rate indicate
that the concentration of local VWF must be much greater than
plasma concentrations to capture the passing platelets at the
observed rate.35 Further, the lag time of slow aggregation could be
explained by the equivalent time of shear activation of mural
platelets to release their a-granule VWF before RPA can occur.13
Based on this evidence, we hypothesized that platelet a-granule
release of VWF and other contents is necessary for RPA to pro
ceed to occlusion beyond the initial platelet attachment to the
subendothelium.31,35,41
In the present study, using in silico fluid dynamic simulations, in vitro
microfluidics, and in vivo models of arterial thrombosis, we
investigated thrombus formation, with and without platelet a-granule
release, at high shear rates. To identify the critical role of platelet
VWF in high shear occlusive thrombosis we used Nbeal22/2 mice
that are deficient in a-granules and therefore do not release platelet
VWF and other contents, but have normal levels of plasma VWF
similar to WT.12
Understanding the time scales, shear rates, and conditions that lead
to occlusive thrombosis under pathological conditions could lead
to better targeted pharmacological inhibitors for the prevention
of arterial thrombosis without bleeding side effects.
Materials and methods
Computational fluid dynamics analysis
Computational fluid dynamics (CFD) analysis was used to predict
shear-rate distribution within microfluidic and carotid artery
geometries. Simulations were performed using Ansys 19.1 (Ansys
Inc, Canonsburg, PA). Whole blood flowing at normal and high
shear rates was assumed to be Newtonian fluid of 3.5 cP, and flow
was presumed to be laminar, incompressible, steady continuum,
and isothermal because of the Reynolds number of the experiments.
The microfluidic chamber was modeled as a rectangular channel
with a total pressure inlet of 4.8 mm Hg and a uniform 0-pressure
(gauge) outlet. The no-slip boundary condition was applied to the
walls (Figure 1A). A stenosed mouse carotid artery was modeled
as a 60% diameter constriction of a cylindrical vessel, and
a 0.25 mL/min flow rate was applied at the inlet, with 0 pressure at
the outlet (Figure 1B). Mesh convergence was achieved at 3.5 million
(microfluidics) and 4 million (mouse carotid artery) tetrahedral cells,
yielding a residual error of 1029 for each model, respectively.
Arterial thrombosis model for simulating
occlusion time
Time to occlusion in a stenotic microfluidic test section or mouse
carotid artery was predicted using a quantitative, empirical high-
shear thrombosis model.45
The model is composed of a lag phase and an RPA phase defined
by
tLag ¼ 1:693106S21:2;
where tLag is lag time and S is the wall shear rate. Thrombus growth
rate during the RPA phase is expressed by time and S.
J ¼

0 ; t# tLag
aebS 1 cedS; t. tLag
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Constants a, b, c, and d are given in Table 1. The lower and upper
confidence limits of thrombus growth are denoted by JMIN and JMAX,
respectively.
Our high shear microfluidic device was modeled as a straight
rectangular channel. Poiseuille flow was assumed and S was
defined by
SRec ¼ 6Qwh2
where the constants Q, w, and h are flow rate, channel width, and
channel height, respectively. Geometry values are specified in Figure 1.
To model the stenosis of the mouse carotid artery, a 60% stenosis
was applied to the diameter of a cylindrical channel to cause an
;50% reduction in flow rate.5 The assumptions of Poiseuille flow














































































Figure 1. Hydrodynamic flow characteristics through a high-shear microfluidic device and stenosed mouse carotid artery. (A) Geometry of the microfluidic model
with an experimental stenotic section. (B) In vivo experiments showing a stenotic region relative to flow direction and flow probe placement. (C) CFD simulations of the
microfluidic device. Blood flowed from left to right. The color contour shows shear strain rate distribution. The solution showed a maximum shear strain rate of .3500 s21 in
the stenosis region, whereas upstream and downstream values were ,1000 s21. (D) CFD simulation in a stenosed mouse carotid artery. The large velocity gradient at the
stenotic apex led to initial shear rates that exceeded 4000 s21. (E-F) Thrombus growth was predicted by using a high-shear thrombosis model developed by Mehrabadi et al.45
Shear strain rate estimation is shown over time during high-shear thrombosis formation in the microfluidic assay and mouse carotid artery. Min and Max denote the lower and
upper confidence limits of the model, respectively.
Table 1. Constants for the RPA phase thrombus growth rate equation
a b (3 1024) c d (3 1026)
JMIN 228.3 21.00 27.4 210.0
JAVG 231.3 21.45 30.7 26.81
JMAX 238.2 21.81 36.6 25.92





















where the constants are defined as in the microfluidic equation, and
d denotes channel diameter.
Channel height/diameter was updated every second as thrombus
growth increased in both models.
Mice
Nbeal22/2 and WT control mice were generated from Nbeal21/2
mice on a C57/bl6 background with a targeted deletion region
between exons 4 and 11 of Nbeal2 (from strain B6;129S5-
Nbeal2tm1Lex/Mmucd).12 An equal number of 12- to 20-week-old
male and female mice were used. All animal experiments were
approved by the university animal care and use committees.
High-shear microfluidic model of stenosis
Microchannels with a stenotic region were used for in vitro studies
of whole-blood occlusion at pathological shear39 (Figure 1A).
Whole blood was collected from the inferior vena cava of
Nbeal22/2 and WT mice into heparin anticoagulant (15 USP
units/mL), and platelets were fluorescently labeled with DiOC6
(3,39-dihexyloxacarbocyanine iodide; Invitrogen). Whole blood was
perfused through the microfluidic device at a constant upstream
pressure head of 65 mm on immobilized type 1 fibrillar collagen
(Chronolog, Havertown, PA). Platelet adhesion and occlusion were
captured in real time with an ORCA Flash4 CMOS camera (Orca‐
ER; Hamamatsu, Hamamatsu City, Japan) and CellSens software
(Olympus, Center Valley, PA), with images being acquired every 1
second for the duration of the experiment. Occlusion time was
defined for each series when centerline red blood cell (RBC)
velocities decreased to less than 100 mm/s.
Folts-like arterial stenosis model
In vivo thrombus formation under pathological shear was assessed
using the Folts-like model of arterial thrombosis.46 A 6.0 silk suture
was tied around the common carotid artery until blood flow rate was
reduced to ;50%, as monitored with a flow probe (Transonic
Systems, Ithaca, NY), to create a stenosis region and a high-shear-
stress environment. The carotid vessel under the stenosis was
gently crushed with forceps, to expose the subendothelial surface,
and blood flow was continuously monitored. Blood flow data were
acquired with Powerlab and analyzed using LabChart Pro version
8.1 (ADInstruments, Colorado Springs, CO). Occlusive thrombus
formation occurred when blood flow decreased to 0. After the
experiments, the carotid artery including the injury site was
dissected and fixed in neutral-buffered formalin fixative overnight.
Tissue was embedded in paraffin, sectioned, and stained either with
hematoxylin and eosin or by the Carstairs method (Electron
Microscopy Sciences, Hatfield, PA). Histology images were captured
with an Olympus BX42 microscope and Olympus DP72 digital
camera with CellSens software (Olympus). Thrombus structure and
composition were assessed where platelets stained blue/purple,
fibrin stained red, red blood cells stained yellow, and collagen
appeared blue.
Analysis
Image analysis was performed with FIJI/ ImageJ 1.51n software
(National Institutes of Health, Bethesda, MD), and the data were
processed with Matlab (Mathworks, Natick, MA). Data analysis was
performed with Prism 7 (GraphPad Software, San Diego, CA).
Statistical significance (P , .05) was determined by the unpaired
Student t test or by a 1-way analysis of variance with the Dunnett
post hoc test for multiple comparisons.47
Results
Hemodynamic flow characteristics through
a high-shear microfluidic device and stenosed mouse
carotid artery
Flow characteristics through a simulated high-shear microfluidic
device (Figure 1A) and stenosis in a mouse carotid artery
(Figure 1B) were quantified through CFDs, and a high-shear
thrombosis growth model was used to predict the occlusion time.45
Our model was simplified by assuming constant flow rate and
upstream pressure as an end point to predict occlusion time.
In microfluidic simulations, the maximum initial shear rate occurring at
the stenotic region of the channel was.3500 s21, and the nonstenotic
upstream and downstream regions were,1000 s21, corresponding to
normal physiological arterial wall shear rates (Figure 1C).
A stenosis with axisymmetric geometry was created to compute shear
rate in a mouse carotid artery model. Simulations were performed with
a 60% stenosis to create an ;50% reduction in flow rate based on
previous studies.5 A maximum initial shear rate of .4500 s21 at the
apex of the stenosis was predicted. No flow separation was seen distal
to the stenosis in this mouse artery because of the low Reynolds
number associated with the small vessel of a mouse (Figure 1D).
A comparison between the microfluidics model and the mouse
carotid artery stenosis model showed that the shear rate distribution
in both stenosis models was very similar (Figure 1C-D). To
determine occlusion times in our simulations, a constant flow rate
was assumed. Occlusion was defined as when the inlet pressure
increased to 4.8 mm Hg with the microfluidic device, and when the
arterial pressure proximal to the stenosis reached 100 mmHg in the
mouse modified-Folts model. Microfluidic device simulations
predicted an occlusion time of 264 6 65 seconds. The mouse
carotid artery with 60% stenosis was predicted to have an
occlusion time of 305 6 77 seconds (;5 minutes). Based on
predicted occlusion times, we made sufficient observation windows
for microfluidics of 8 minutes and for the mouse carotid artery of
12 minutes. The shear rate and simulated thrombus growth built up
in the microfluidic channel and stenosed mice artery, as shown in
Figure 1E-F, where the shear rate was calculated to increase as
high as 10 000 and 100000 s21, respectively.
Platelet VWF released by shear is necessary for
forming subsequent occlusive thrombi
To isolate the contributions of platelet VWF to the formation of
occlusive thrombus at high shear, we performed perfusion assays
on type 1 collagen in microfluidic channels that mimic the stenosis
of arteries using WT and Nbeal22/2 mouse whole blood. The
hemodynamics previously quantified through CFDs were recapitu-
lated in our device. Whole blood was perfused through the device
under a constant upstream pressure of 4.8 mm Hg to create wall
shear rates of ;3500 s21 at the stenosis and ,1000 s21 at the
nonstenosis regions (Figure 1C). RBC centerline velocities distal to
the thrombi ,100 mm/s were used to define the occlusion time.
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WT mice formed characteristically normal thrombi at the stenotic test
section (Figure 2A). An initial lag phase of continuous adhesion and
aggregation (see adherent platelets at 1 minute) was proceeded by an
RPA phase characterized by an increase in thrombus size and
intensity (Figure 2C). WT mice occluded the microfluidic stenosis test
region within 326 6 25 seconds (Figure 2C) as measured by RBC
flow (n 5 6; P , .001). In contrast, Nbeal22/2 mouse whole blood
exhibited a normal lag phase adhesion of platelets to collagen within
the first minute, but then no RPA phase or occlusion was observed
during the next 8 minutes of follow-up (Figure 2B-C; n5 6; P, .001).
To further demonstrate that normal plasma VWF alone is not enough
to form occlusive thrombus, we then reperfusedWTwhole blood into
the nonoccluded Nbeal22/2 channels (Figure 2B). Perfusion of WT
led to immediate RPA of the earlier collagen-bound Nbeal22/2
platelets, and occlusion was observed 166 6 48 seconds later
(Figure 2D). Collectively these results conclusively demonstrate that
plasma VWF supports the primary adhesion of platelets to collagen
during a lag phase, whereas platelet VWF is essential for RPA and
occlusive thrombus formation at high shear rates.
Platelet VWF release induces localized formation of
an occlusive thrombi
Localized release of VWF from activated platelets could induce





























































9 min 10 min 13 min
Figure 2. Plasma VWF is sufficient for initial adhesion of platelets to collagen, whereas platelet VWF released locally is necessary for forming subsequent
occlusive thrombi. Representations of WT and Nbeal22/2 platelet adhesion and subsequent occlusion during the 8-minute perfusion period. The progressive accumulation
of platelets is observed over time. (A) WT mice blood showed rapid and significant platelet adhesion and aggregation leading to occlusion. (B) Nbeal22/2 mice blood did not
form occlusive thrombi during the 8-minute observation period. Occlusive thrombi formed after the addition of WT whole blood (Rescue) to Nbeal22/2 platelets adherent to
collagen. The 1-mm stenosis region is marked with a red line under the image. The ROI appears blank before the adhesion of platelets (green; 3,39-dihexyloxacarbocyanine
iodide [DiOC6]). Flow direction is from left to right. The bar represents 1000 mm. (C) Normalized fluorescent intensities comparing thrombus growth and occlusion in control
WT (n 5 6), Nbeal22/2 (n 5 6), and Rescue (n 5 3) channels. Initial lag phase quickly proceeded to RPA, demonstrated by a rapid increase in thrombus size and intensity at
;100 seconds for WT whole blood and at 515 6 47 seconds for Nbeal22/21WT whole blood. Occlusion occurred at the end of the plot for WT and Nbeal22/21WT whole
blood. No occlusion was observed with Nbeal22/2 whole blood alone. The arrow denotes the time point when WT whole blood was added to Nbeal22/2 channels. All images
were postprocessed and averaged to compare the intensity levels in the test sections. (D) Occlusion times in the microfluidic device for WT (326 6 25 seconds), Nbeal22/2
(no occlusion), and Nbeal22/21WT (166 6 48 seconds). All 3 occlusion times were significantly different from each other. ***P , .001.
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channels and gravity-driven flow, Griffin et al48 found that localized
thrombi formed with human blood. To investigate whether the same
effect would occur with mouse blood, we split the region of interest
(ROI) into 3 ROIs (Figure 3A) and compared the intensity level of
each ROI. The final intensity level in ROI 1 (upstream) was
significantly higher than that in the other 2 ROIs for WT and Rescue
(Figure 3B; P, .01), but there was no significant difference between
ROIs for Nbeal22/2. The intensity level of each ROI during the
perfusion time (Figure 3C-D) showed a sudden increase in intensity
in ROI 1 for WT (80 seconds) and Rescue (20 seconds), but only
a small increase in intensity in ROIs 2 and 3. Thus, RPA occurs in the
upstream part of the stenosis (333 mm) and serves as the dominant
location for the channel occlusion in the microfluidic system.
An absence of platelet VWF prevents occlusive
thrombus formation in the Folts-like arterial
stenosis model
To investigate the contribution of platelet-derived VWF in promoting
occlusive thrombus formation in vivo, we used WT and Nbeal22/2
mice in a modified Folts arterial model.15 A stenosis was made by
decreasing blood flow in the carotid artery by ;50% and
generating a high-shear-stress zone. Occlusion occurred in all
WT mice at an average time of 330 seconds after deendothelization
of the stenosed vessel. In contrast, no occlusive thrombus formation
was observed in the carotid arteries of all Nbeal22/2 mice (Figure
4A-B; n 5 7; P , .0005).
Histological examination using Carstairs stain revealed that the
thrombi in the occluded arteries of WT mice were platelet rich,
whereas histology and macroscopic imaging showed an absence of
thrombi at the vessel injury site in Nbeal22/2 mice (Figure 4C-D).
These findings indicate that VWF from platelet a-granules is
necessary for occlusive thrombus formation in a stenosed artery.
Platelet VWF is critical for the RPA phase and
subsequent vessel occlusion
Mehrabadi et al45 modeled high-shear thrombosis with 2 phases:
lag and RPA. We applied their thrombosis growth model for
microfluidics and mouse carotid artery, comparing occlusion times.
Microfluidic simulations of an 82-mm-height channel predicted a lag
phase time of 138 seconds, followed by an RPA phase of 109
seconds, resulting in a total occlusion time of 247 seconds, which is














































































Figure 3. Platelet VWF induces localized formation of occlusive thrombi. (A) Three ROIs were delimited for the microfluidic channel test section. (B) Normalized
fluorescence intensity level of each ROI after an 8-minute perfusion for WT (n 5 6) and Nbeal22/2 (n 5 3) and 5 minutes for Rescue (n 5 3). ROI 1 showed a significantly
higher intensity level with WT and Rescue, compared with ROIs 2 and 3. **P , .01; ***P , .001. There was no significant increase in ROI 1 with Nbeal22/2 blood. (C-D)
Intensity levels of each ROI during the perfusion time. The arrow denotes the time point when WT whole blood was added to Nbeal22/2 channels. The intensity level of ROI 1
rapidly increased after 80 seconds in the WT and 20 seconds in the Rescue mice. ns, not significant.
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Nbeal22/2 mouse whole blood did not advance past the lag phase,
and no RPA was observed. However, when new exogenous WT
mouse platelets were perfused through to the same device channel
containing Nbeal22/2 adherent platelets, the RPA phase occurred
almost immediately (bypassing its own WT lag phase). Subtracting
the lag time of the Nbeal22/2 platelets from the RPA phase of the
WT platelets showed an occlusion time of 170 6 57 seconds,
which was comparable to the predicted value for RPA occlusion of
138 seconds (Figure 5).
In simulations of a mouse carotid artery stenosed to 60% of its
diameter, the modeled occlusion time was calculated as 305 seconds,
which was similar to the results of in vivo experiments in WT mice,
which exhibited a mean occlusion time of 352 seconds (Figure 5).
Discussion
We investigated the role of platelet VWF in high-shear occlusive
thrombus formation using a combination of CFDs: high-shear
in vitro microfluidics and in vivo stenosis model of arterial
thrombosis. Many studies of platelets investigate attachment at
physiological shear rates. Here, high-shear thrombus formation is
different from physiological platelet attachment because of the


























































H&E Carstairs H&E Carstairs
20


















Figure 4. An absence of platelet VWF prevents occlusive thrombus formation in the modified Folts arterial stenosis model. (A) Mean blood flow through the
carotid artery was reduced to 50% by making stenosis and subsequently crush injury was induced. WT mice consistently formed an occlusive thrombus in response to the stenosis and
crush injury. In contrast, there was no occlusive thrombus formation in the carotid artery of the Nbeal22/2 mouse (n 5 7, bar shows 6 standard error of the mean [SEM]; P , .0001).
(B) WT mice formed occlusive thrombi at an average time of 330 seconds after deendothelization of the stenosed vessel. Nbeal22/2 mice were unable to form occlusive thrombi in vivo
(n 5 7, bar shows 6 SEM; P , .0005). (C) Representative macroscopic images of the gross anatomy of an excised carotid artery from WT and Nbeal22/2 mice. The WT carotid
features a prominent clot (arrows) within the longitudinal arterial lumen (outlined) suggesting the presence of an occlusion. There is a clear absence of occlusive matter within the lumen






















































Figure 5. Comparison of simulated occlusion
times vs actual experimental values. (A) In vitro
microfluidics. (B) In vivo mouse carotid artery mod-
ified Folts model.
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atherosclerotic stenosis in a critical artery. As thrombus formation
progresses at these stenoses, the diameter of the throat narrows,
further increasing the shear rates. Flow occlusion and occlusion time
are relevant end points that correspond to acute coronary syndrome.
Using models that closely mimic the geometries of stenotic arteries,
we recapitulated the time to occlusive thrombosis and correlated and
compared in silico simulations with in vitro and in vivo experiments.
The microfluidic channel and mouse carotid artery were modeled
and simulated by calculating the shear rates through their
respective geometries. Using the predicted shear rates, occlusion
times were determined with a 2-phase model.45 Comparisons with
WT experimental data showed that the model could predict shear
rates and occlusion times for a ;60% stenosis where normal
plasma and platelet VWF was present. Knowing that our model had
good predictivity for normal WT whole blood, we went on to
determine the individual contributions of VWF in the plasma and
platelet compartments of whole blood in Nbeal22/2 mice that do
not have a-granules and consequently no platelet VWF.12 Re-
capitulating the CFDs, we found that Nbeal22/2 mice blood could
not form occlusive thrombi in microfluidic chambers as compared
with WT blood. In the microfluidic assays, Nbeal22/2 platelets only
minimally adhered to collagen under high shear during the lag
phase. No RPA or occlusion in the microchannels was observed
with Nbeal22/2 mouse blood. Amelioration of the RPA phase was
observed when WT platelets with normal platelet VWF were perfused
through the same microfluidic channel. This effect was sufficient to
restore normal RPA and localized occlusive thrombus formation as
a Rescue study.Wewere able to validate thatNbeal22/2 platelets also
showed impaired thrombus formation in vivo using a modified Folts
model with high shear compared with WT controls. By correlating
shear rates from computational fluid dynamics modeling, this work
could be used to predict the thrombogenic potential of implanted
blood contacting medical devices, such as artificial circulation and
heart valves, that are prone to causing occlusive arterial thrombosis.49
Although platelet VWF is of central importance for the formation
of shear-resistant occlusive thrombosis under these pathological
experimental shear rates, it cannot be ruled out that other a-granule
adhesive proteins and coagulation factors may also contribute to this
process, although the contribution of these proteins at pathological
shear may be less significant. Future studies in transgenic mice in which
platelet VWF is ablated are needed to further dissect this mechanism.
Our Nbeal22/2 mice did not contain platelet VWF, and their plasma
VWF levels were normal. In WT platelets, the VWF inside
a-granules was 50-fold higher than the concentration of plasma
VWF27 and was capable of mediating platelet adhesion.3000 s21
. 29 As platelets become activated and release their a-granule
contents, the localized release of high concentrations of ULM VWF
is delivered directly to the thrombus cap. Although Nbeal22/2 mice
are reported to have mild thrombocytopenia,12,24 previous reports
have shown that severe platelet count reduction, including the
thrombocytopenia phenotype observed in Nbeal22/2mice, have no
major effect on hemostasis and thrombosis.23,24,50 Therefore, it is
highly unlikely that our thrombotic defect was related to a reduced
platelet count in Nbeal22/2 mice.
In in vivo experiments using the common carotid artery, shear rates
at the stenosis where there was a 50% reduction in blood flow were
estimated to be .4600 s21. Under these conditions, similar to
human thrombus formation, mouse platelet thrombus formation at
this shear is assumed to be VWF dependent. Though platelet
activation and coagulation are mutually dependent processes, we
speculate that in vivo platelet VWF in occlusive thrombosis is
coagulation pathway independent, most likely because of the rapid
transport away of coagulation factors and the diffusion of assembled
coagulation factors at the site of vascular damage by increased
pathological shear rates. We used heparinized (15 USP units/mL)
whole blood in vitro, so that we could investigate specific platelet-
matrix/platelet-platelet interactions without coagulation while trans-
porting the blood. In the in vitro experiments, in the absence of
coagulation, we observe RPA (and occlusion) only when platelet (and
plasma) VWF was present. Occlusion did not occur in the absence of
coagulation and platelet VWF. Although the interpretation of the in vitro
results cannot be directly compared against in vivo results where
coagulation can occur, the study still demonstrates that platelet VWF is
required for occlusive thrombosis to occur in both models. These
findings demonstrate that a-granule–derived VWF, released after
activation, contributes to thrombus growth independent of the plasma
VWF levels that would aid initial platelet adhesion before activation.
In conclusion, the results of this study show the importance of shear-
induced platelet VWF release that creates an occlusive thrombus.
Theoretical predictions combined with in vitro and in vivo experiments
isolated the necessary role of a-granules for large thrombus formation.
Current antithrombotic therapeutics are unable to distinguish between
physiological and pathological shear rates without affecting hemosta-
sis. The requirement of platelet VWF to bind platelets under high-shear
conditions, like those in stenotic arteries, makes it a potential novel
target for pharmacological intervention to prevent pathological
thrombus formation in myocardial infarction or stroke.
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